Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.55]
1 study · 104 participants
Low

Serious adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.31 [0.03, 3.21]
1 study · 104 participants
Low

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.82 [0.04, 16.34]
1 study · 104 participants
Low